Dr. Pagdin Bioidentical Hormone Replacement Therapy for Women
CIRCLE OBJECTIVE
Bioidentical Hormone Replacement Therapy (“BHRT”) is used to help treat female hormonal conditions. BHRT products are prescribed by clinicians and prepared by compounding pharmacies. This Circle captures symptoms and health-related quality-of-life data from pre- and post-administration of BHRT for 18 months. Outcome measures include the Cervantes Short-Form Scale and the Heavy Menstrual Bleeding-Visual Analog Scale. Aggregated Circle datasets will provide clinically significant evidence relating to safety and efficacy of BHRT for female patients.
Grant Pagdin MD
FOUNDER
MDBiologix
FUNDER
CIRCLE OBJECTIVE
Bioidentical Hormone Replacement Therapy (“BHRT”) is used to help treat female hormonal conditions. BHRT products are prescribed by clinicians and prepared by compounding pharmacies. This Circle captures symptoms and health-related quality-of-life data from pre- and post-administration of BHRT for 18 months. Outcome measures include the Cervantes Short-Form Scale and the Heavy Menstrual Bleeding-Visual Analog Scale. Aggregated Circle datasets will provide clinically significant evidence relating to safety and efficacy of BHRT for female patients.

Circle Protocol

Patient Reported Outcome Measure:
C-SF; HMB-VAS
Intervention:
Bioidentical Hormone Replacement Therapy (BHRT)
Clinical Benefits:
Streamlined patient enrollment, real-world data capturing, heightened recognition, prominence and collaboration
Patient Benefits:
Personalized, secure, and simple to use

MEMBER criteria

Require approval to join from Circle Founder, Dr. Grant Pagdin

FEATURED CIRCLE ELEMENTS

No items found.

THE LATEST NEWS

Left arrow in circle
Right arrow in circle
No items found.

Dr. Pagdin Bioidentical Hormone Replacement Therapy for Women

Status:

Private

Study TYPE:

Quality Improvement, Interventional, Open-Ended

Study Abstract:

Bioidentical Hormone Replacement Therapy (“BHRT”) is used to help treat female hormonal conditions.  BHRT products are prescribed by clinicians and prepared by compounding pharmacies.  This Circle captures symptoms and health-related quality-of-life data from pre- and post-administration of BHRT for 18 months.  Outcome measures include the Cervantes Short-Form Scale and the Heavy Menstrual Bleeding-Visual Analog Scale.  Aggregated Circle datasets will provide clinically significant evidence relating to safety and efficacy of BHRT for female patients.

Outcome measure:

Cervantes Short-Form Scale; Heavy Menstrual Bleeding-Visual Analog Scale

PRIMARY ENDPOINT:

Clinically significant reduction in scores collected from the Cervantes Short-Form Scale at 6-months post-treatment.

InvestigatorS:

Grant Pagdin, MD.  Canadian board-certified in Family Medicine, American Academy of Anti-Aging and Regenerative Medicine (ABAARM).  Fellowship in Family Medicine (FCFP).  Fellowship in Stem Cell Medicine.  Fellow with the Interventional Orthobiologics Foundation.

CIRCLE RELEVANT TO:

Endocrinologists, family practice and other primary care physicians, compounding pharmacies, obstetricians- gynecologists, advanced practice nurses and physicians assistants.

Circle Benefits:

Collaboration with nationally recognized musculoskeletal physicians.  Participate and benefit from clinically significant registry datasets supporting standards of care for a variety of musculoskeletal indications.  Drive superior patient education and engagement.  Legal/regulatory compliance.  Support payer negotiations.